Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The market for insulinoma treatment is stimulated by the growing incidence of insulinoma instances globally. As the prevalence of this uncommon pancreatic neuroendocrine tumor grows, the demand for effective remedy options, such as pharmaceutical interventions, is on the rise. The improvement and adoption of superior diagnostic technology play a pivotal function in shaping the insulinoma treatment market. Improved imaging techniques and diagnostic tools are useful resources in the early and accurate detection of insulinomas, riding the demand for therapeutic interventions. Increased focus on insulinoma and its symptoms among healthcare experts and the general population has led to early diagnosis. Early detection is crucial for a successful remedy, and the emphasis on timely identification is a key factor in the market boom. Ongoing research and improvement sports within the field of neuroendocrine tumors, mainly insulinoma, make contributions notably to market dynamics. Pharmaceutical companies investing in innovative remedy techniques and drug improvement are instrumental in expanding the to-be-had remedy alternatives.
Collaborations among pharmaceutical corporations, research institutions, and healthcare groups are fostering a collaborative environment. Such partnerships facilitate knowledge trade, the pooling of resources, and the acceleration of insulinoma treatment development, impacting the market boom in the long run. The insulinoma treatment market is motivated by the aid of continuous advancements in healing modalities. From traditional surgical procedures to minimally invasive techniques, technological improvements contribute to the diversification of treatment options, catering to patient options and medical improvements. Accessibility and affordability of insulinoma treatment options play a critical role in market dynamics. Government policies, insurance coverage, and efforts to make superior remedies more handy to a broader affected person populace contribute to the market's expansion. The presence of more than one player in the insulinoma treatment market intensifies competition. New entrants and mounted pharmaceutical groups vying for market percentage drive innovation, foster competition, and make contributions to the evolution of remedy alternatives.
Demographic elements, which include getting old populations and changing life, contribute to the general sickness burden, together with insulinoma. As demographic developments evolve, the market for insulinoma treatment adjusts to satisfy the healthcare needs of various populations. The regulatory panorama governing drug approvals and market entry is a vital element in shaping the insulinoma treatment market. Timely approvals, adherence to regulatory requirements, and a supportive regulatory environment affect market dynamics. Increasing affected persons' choice for non-invasive remedy alternatives, such as centered treatment options and scientific control, affects the insulinoma treatment market. This shift in patient preferences encourages the improvement of less invasive and more effective person-friendly interventions.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Growth Rate | 6.9% (2022-2030) |
Insulinoma Market Highlights:
Insulinoma Market Overview
The Insulinoma Market is expected to reach USD 5,632.6 Million by 2030 at 6.9% CAGR during the forecast period 2022-2030.Insulinoma is a rare form of tumour of the beta cells of pancreas resulting in an excessive secretion of insulin, leading to hypoglycaemia. Most insulinomas are benign, however a few metastasize. The symptoms of insulinoma are hypoglycaemia and associated symptoms such as blurred vision, lethargy, diplopia, light headedness, and convulsions, unconsciousness, which can also be life-threatening. Severe hypoglycemia may result in seizures, coma, and permanent neurological damage. Symptoms such as palpitations, tachycardia, sweating, hunger, anxiety etc. are caused by catecholaminergic response to hypoglycaemia triggered by insulinomas.
Insulinomas occur in people between the ages of 40 and 60 and grow slowly. The exact causes of insulinoma are unknown, however, patients with multiple endocrine neplasia type 1 syndrome or von Hippel-Landau syndrome are more at risk. According to a cancer research, 10% of insulinomas are cancerous and approximately 10% of patients diagnosed with insulinoma have more than one tumour. Insulinomas affect between up to five people out of one million each year.
Surgery is the definitive treatment for insulinomas and 90% of patients are cured of the condition. However, surgery can cause diabetes if significant amount of the pancreas are removed. The development of minimal invasive surgery procedures such as laparoscopy has resulted in replacement of open pancreatomy which was once the gold standard of treatment. The market constraints are lack of awareness, misdiagnosis of the disease, risk of surgery, high cost of treatment etc.
March 2021: Zealand Pharma A/S, a biotechnology company that aims to bring innovation to the market through the development of innovative peptide therapeutics, announced today that the U.S. The Food and Drug Administration (FDA) has approved Zegalogue® (dasiglucagon) injection for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and older. This sanction will facilitate the ability of suitable children and adults with diabetes to manage sudden and severe hypoglycemia, which can rapidly escalate from a mild occurrence to an emergency. The clinical significance of the extent and consistency of the effect observed in the Phase 3 pivotal studies is underscored by the fact that minutes are crucial in severe hypoglycemia. Zegalogue resolved severe hypoglycemia after administration, with a median time to blood glucose recovery of 10 minutes in these clinical studies. A critical drop in blood glucose levels, which is predominantly associated with insulin therapy, is the cause of severe hypoglycemia, an acute, life-threatening condition that is one of the most feared complications of diabetes treatment. The prevalence of severe hypoglycemia among children under the age of 18 is particularly high, with 7 out of 100 children diagnosed with diabetes on insulin reporting such episodes within the past six months. Although patients have the capacity to monitor and adjust their blood glucose levels to maintain appropriate glycemic control, it is not always feasible to prevent a severe hypoglycemic event.
July 2021: Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company that utilizes its innovative formulation technology platforms to create and market injectable and infusible drug formulations that are ready to use, announced that Gvoke HypoPen™ (glucagon injection) is now available by prescription in the United States for the treatment of severe hypoglycemia in adults and children with diabetes aged 2 years and older. The Gvoke HypoPen is the first premixed autoinjector that is ready to use and does not have a visible needle. It contains glucagon. Xeris is dedicated to guaranteeing that patients have access to this significant new development. Using the Gvoke® copay savings card, eligible commercially insured patients may pay as little as $0 for a two-pack of Gvoke HypoPen for a limited time. Additionally, Xeris provides a Patient Assistance Program to assist individuals who meet the eligibility criteria for Gvoke.
Research Methodology 
Intended Audience
- Global insulinoma treatment manufacturers & suppliers
- Research and development (R&D) companies
- Hospitals and clinics
- Academic institutes and universities
Figure 1 Global insulinoma market by types, 2016 (%)
Insulinoma Market Segmentation
The global insulinoma market has been segmented on the basis of type, diagnosis, treatment, and end user.
Based on type, the market has been segmented as benign, and metastasize.
Based on diagnosis, the market has been segmented as blood test, endoscopic ultrasound, Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and others.
Based on treatment, the market has been segmented as surgery, drugs, radiofrequency ablation, chemotherapy and others.
Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.
Insulinoma Market Regional Analysis
The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new products and surgical procedures in the US drives the insulinoma market. Also, concentration of major healthcare companies in the developed countries of this region coupled with the larger insurance penetration is adding fuel to the market growth. Moreover, the US expend high on the healthcare, which accounts for 16% of GDP also cruises the sale of insulinoma treatment.
Europe is the second largest market in the world due to high income and strong healthcare penetration. European market growth is led by countries such as Germany and France. The UK is expected to be the fastest growing market over the assessment period.
Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs during the forecast period. South East Asian countries such as Vietnam, Thailand, and Malaysia are projected to contribute highly to the market growth.Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for will be Kuwait, Jordan, Egypt and Iran.
The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development. However, Africa has the highest unmet needs in the world and cost-effective products will be the key to dominate the African market.
Key Players in the Global Insulinoma Market
Some of key players profiled in the report are
- Abcam plc,
- cironpharma,
- Pfizer Plc.,
- Entax Medical,
- Olympus,
- Boston Scientific Corporation,
- Medtronic,
- Cook Medical,
- Cook Medical, Inc., and
- others.
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
